Formulation of chitosan-based ciprofloxacin and diclofenac film for periodontitis therapy by Ahmed, MG et al.
Adisa et al 
Trop J Pharm Res, February 2009; 8 (1): 33 
Tropical Journal of Pharmaceutical Research, February 2009; 8 (1): 33-41 
© Pharmacotherapy Group,  
Faculty of Pharmacy, University of Benin,  
Benin City, 300001 Nigeria.  
All rights reserved. 
 




Formulation of chitosan-based ciprofloxacin and 
diclofenac film for periodontitis therapy 
 
Mohammed Gulzar Ahmed*, NM Harish, R Narayana Charyulu, 
Prabhakar  Prabhu 





Purpose: This study was designed to develop and evaluate chitosan films containing ciprofloxacin and 
diclofenac sodium for the topical treatment of periodontitis.  
Methods: Chitosan films containing ciprofloxacin alone and in combination with diclofenac sodium were 
prepared by solvent casting method. Some of the drug-loaded films were crosslinked with 2% 
gluteraldehyde for 2 and 4 h, respectively. The films were then evaluated for their physicochemical 
properties including weight variation, thickness, tensile strength, in vitro release, stability and 
antibacterial activity.  
Results: Mean weight and thickness data showed that the different films were uniform. Tensile strength 
was maximum for drug-free films and minimum for films containing the highest amount of drug(s). In 
vitro drug release data indicate that the films showed an initial burst release followed by sustained 
release of the drug(s). Films stored at refrigerated conditions exhibited slower degradation rate. The 
drug-loaded films that were  crosslinked  for 4 h had inhibitory effect on Staph mutans for up to 24 days. 
Conclusion: The study suggests that crosslinked chitosan film containing ciprofloxacin and diclofenac 
is a potential drug delivery device for the topical treatment of periodontitis. Good physicochemical 
properties were shown by the films. 
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INTRODUCTION 
 
Periodontal diseases are infections affecting a 
significant proportion of people in all 
populations
1
. The presence of periodontal 
pathogens such as Porphyromonas gingivalis,  
Prevotella intermedia and Actinobacillus 
actinomycetemcomitans are responsible for 
periodontal destruction
2
. Therefore, an 
objective of periodontal treatment is to 
suppress or eliminate subgingival periodontal 
pathogens. This is generally achieved through 
subgingival debridement, resulting in the 
reduction of the total bacterial load
3
. However, 





and this may be 
due to some periodontal pathogens that are 
inaccessible during mechanical periodontal 
therapy. On the other hand, it is conceivable 
that local and/or systemic administration of 
effective antimicrobial agents may enhance 




Systemic antimicrobials such as adjuncts to 
mechanical therapy have had a positive 
effect on clinical as well as microbiological 
parameters
6
. But the impact of this approach 
is reduced by the fact that the antibiotic is 
normally difficult to maintain in therapeutic 
concentrations at the site over the course of 
the treatment period. Moreover, systemic 
antibiotic therapy carries with it the risk of the 
host developing resistance.  Due to these 
negative effects, the use of local drug delivery 
devices containing antibiotics which can 
maintain therapeutic concentrations at the site 
of infection is an approach that may be 
explored. This could enhance the therapy of 





Pharmacological agents applied locally for the 
treatment of periodontitis are targeted to 
several areas such as bacteria in periodontal 
pockets, soft tissue walls of the pocket, and 
the exposed root cementum. Experimental 
evidence suggests that many forms of local 
delivery are not able to deliver medications to 
all these locations. For example, agents in 
mouth rinses and those used for irrigation do 
not predictably reach beyond 5 mm into the 
periodontal pocket
8
. On the other hand, 
gaining access to the anatomical boundaries 
of the pocket does not mean penetration to 
the target bacteria, because bacterial 
aggregates (biofilm) impair diffusion or 
inactivate pharmacological agents. Also, rapid 
turnover of gingival crevicular fluid in the 
sulcus rapidly reduces the concentration of 
the locally placed antimicrobial agent
9
. It has 
been shown that the fluid present in a 5 mm 
pocket is replaced about 40 times an hour. 
This high rate of clearance represents a major 
obstacle to maintenance of effective 





Earlier, it was hypothesized that local 
production of prostaglandins and other 
metabolites of arachidonic acid within the 
periodontal tissues contributes to alveolar 
bone resorption in periodontitis. Research 
findings have shown that inhibitors of 
prostaglandin production, such as non-
steroidal anti-inflammatory drugs (NSAIDs), 
could affect the course of bone loss in 
periodontal disease
11
. Data from prospective 
animal experiments and human studies 
support this concept, and indicate that 
NSAIDs can reduce gingival inflammation and 
reduce alveolar bone resorption
12
. There is 
also evidence that systemic administration of 
antibiotics and NSAIDs are effective in altering 





Chitosan is a hydrophilic biopolymer obtained 
by alkaline deacetylation of chitin, a major 
component of arthropod shells, and 
possesses favorable properties such as non-
toxicity, biocompatibility, bioadhesivity and 




Ciprofloxacin is a second generation 
fluroquinolone derivative, exhibiting activity 
against a wide range of Gram-negative and 
Gram-positive facultative bacteria as well as 
periodontal pathogens
15
. Diclofenac sodium 
has analgesic, antipyretic and anti-
inflammatory activities. It is a non-selective 
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cyclo-oxygenase inhibitor with potency greater 
than several other NSAIDs. In addition, 
diclofenac appears to reduce the intracellular 
concentration of free arachidonate in 
leucocytes, perhaps by altering the release or 




Therefore, an attempt has been made in this 
study to develop chitosan films containing an 
antibiotic, ciprofloxacin hydrochloride, and an 
NSAID, diclofenac sodium, for the treatment 






Ciprofloxacin was a gift from Dr. Reddy’s 
Laboratory, Hyderabad, India. Diclofenac 
sodium from Eros Pharmaceuticals, 
Bangalore, India; chitosan from Central 
Institute of Fisheries Technology, Kochi, India; 
and HPLC-grade solvents from Ranbaxy Fine 
Chemicals Ltd, India, were also used in the 
study.  
  
Preparation of ciprofloxacin-loaded 
chitosan films 
 
Chitosan (2 g) was soaked in 100 ml aqueous 
acetic acid solution (1% v/v) for 24 hour to get 
a clear solution, which was later filtered 
through a muslin cloth to remove undissolved 
polymer (chitin). Ciprofloxacin (0, 10, 20 and 
30 % w/w based on the weight of chitosan) 
was incorporated in 100 ml of chitosan 
solution and vortexed (Talboys, Standard 
Vortex Mixer) for 15 min. The viscous 
dispersion was kept aside for 30 min for 
complete expulsion of air bubbles. Films were 
cast by pouring the drug-polymer solution into 
the center of glass moulds and allowed to dry 
at room temperature. The dry films were cut 
into strips of (7 × 2 mm), wrapped in aluminum 
foil and stored in a calcium chloride desiccator 
at room temperature pending evaluation. 
Preparation of chitosan films containing 
ciprofloxacin and diclofenac sodium followed 
the same procedure
17
. The compositions of 
the films are stated in the footnotes of Tables 
1 and 2. 
 
Preparation of crosslinked chitosan films 
 
The films containing 30% drug(s) were 
crosslinked by exposure to glutaraldehyde 
vapor in a chromatography chamber. The 
chamber was previously saturated with the 
vapour of 2%v/v glutaraldehyde for 24 h; the 
films were exposed to the vapour for 2 and 4 
h, respectively, and then dried.  The dry films 
were cut into strips (7 × 2 mm), wrapped in 
aluminium foil and stored in a calcium chloride 




Evaluation of drug-loaded chitosan films 
Infra-red (IR) spectroscopy  
 
Compatibility studies were conducted, using 
FT-IR spectroscopy, on the drug(s) alone, the 
polymer alone and the drug with polymer by 
potassium bromide cup method. Mixtures of 
drug alone and drug with polymer were 
examined under nitrogen to eliminate 
oxidative and pyrolytic effects at a standard 
heating rate (2.5 or 10
0
C/ min). The samples 
were kept in sealed glass vials for 2 weeks at 
60
0 
C and observed for any physical change in 





Selected film parameters 
 
Various film properties such as size, 
thickness, content uniformity, weight variation 
and moisture loss were determined. The 
thickness of three films (1×1 cm) was 
determined at six different points on the film 
using a film thickness tester (Mitutoyo 4026F, 
Japan)
15
 and the mean calculated. Individual 
weights of twenty films of the same size (7×2 
mm) were weighed on an electronic balance 
and the mean weight was calculated
16
.  
Percent moisture loss was determined by 
keeping the film in a desiccator containing 
anhydrous calcium chloride. After three days, 
the films were taken out, re-weighed and the 
percent moisture loss was calculated using 
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Tensile strength and elongation  
 
Tensile strength was evaluated using an 
Instron Universal Testing instrument (Model 
4206, Instron Ltd., Japan) with a 2 kg load 
cell. Films of the required dimension and free 
from air bubbles or physical imperfections 
were held between two clamps positioned at a 
distance of 3 cm. During measurement, the 
top clamp, at a rate of 100 mm/min, was 
pulled, and the force and elongation were 
measured when the film broke. Only results 
from film samples that broke between the 
clamps were used. Measurements were run in 
triplicate for each film. Tensile strength and 
percent elongation were calculated by 




Tensile strength = Force at break (N)/Initial cross 
sectional area of the sample (mm
2
)  …………..(1) 
 
% Elongation = (Increase in length/original length) 
x 100 ………………………..............................  (2) 
 
Estimation of content uniformity 
 
The drug-loaded films of known weight (7 × 2 
mm) were dissolved in 10 ml of aqueous 
acetic acid, suitably diluted and the amount of 
drug(s) present was estimated by UV/VIS 
spectrophotometer ( Jasco V-530) at 278 
nm
14
.    
 
In vitro drug release studies  
 
Since the pH of gingival fluid lies between 6.5 
– 6.8, phosphate buffer pH 6.6 was used as 
simulated gingival fluid. Also, since the film 
should be immobile in the periodontal pocket, 
a static dissolution model was adopted for the 
dissolution studies.  Sets of six films of known 
weight and dimension were placed separately 
in small sealed test tubes containing 1.0 ml of 
phosphate buffer (pH 6.6) and kept at 37 ± 0.5 
°C for 24 h. The buffer was then drained off 
and replaced with a fresh 1.0 ml of buffer. The 
concentration of drug(s) was determined by 
UV/VIS spectrophotometer (Jasco V-530) at 
278 nm and 273 the procedure was continued 
for 7 and 21 consecutive days for non-
crosslinked and crosslinked films, 
respectively. Following the in vitro release 
studies, the test films were further analyzed 
for unreleased drug by dissolving the films in 
aqueous acetic acid with suitable dilution. The 
amount of drug released into the dissolution 
medium plus residual drug content of the films 





Scanning electron microscopy (SEM) 
 
The morphology and surface topography of 
the films were examined by SEM (model JSM-
840 A, SEM–Jeol, Japan). Spherical samples 
(5 mm
2
) were mounted on the SEM sample 
stab using a double-sided sticking tape. The 
samples were coated with gold (200 A
0
) under 
reduced pressure (0.001 torr) for 2 min using 
an ion sputtering device (model JFC-1100 E, 
Jeol, Japan). The gold-coated samples were 
observed under the SEM and 
photomicrographs of suitable magnifications 
were obtained
18
.   
 
In vitro antibacterial activity 
 
In vitro antibacterial activity was performed on 
all formulations by placing the film,  0.5 × 0.5 
cm, on  agar plates seeded with the oral 
bacteria Streptococcus mutans. After 48 h of 
incubation at 37°C, the films were transferred 
to freshly seeded agar plates and incubated 
for an additional 48 h. This procedure was 
repeated until no inhibition of bacterial growth 
was detected on the agar plate. The growth 





Stability studies  
  
Three sets (12 strips in each set) of films 
(size: 7×2 mm) were weighed. The films were 
wrapped individually in aluminium foil and 
butter paper (30 GSM, Shree Ganesh 
Industries, New Delhi) and placed in Petri 
dishes. These containers were stored at 
ambient humidity conditions in a refrigerator 
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(Labtop, LLR-290 at 4-8ºC), at room 
temperature (25 ± 2ºC) and in an oven 
(Steridium, 140, Australia)at 45 ± 2ºC). The 
samples were analyzed for physical changes 
such as color and texture. Drug content was 
estimated at regular intervals as described 
earlier and the degradation rate constant, k, 
was determined by graphical method (log % 
drug remaining vs time)
21




The amount of drug added to the polymer 
solution altered the film characteristics.  The 
optimum drug loading was less than 30% w/w 
of the polymer.  At higher drug loadings (i.e., > 
30%), the films were stiff and brittle. 
 
The results of the physicochemical 
evaluations are presented in Table 1. Moisture 
loss varied between 4.4 ± 2.2 and 9.9 ± 1.0%. 
Tensile strength was lowest for uncrosslinked 
films and highest for crosslinked films and was 
in the range, 0.541 - 1.87 kg/mm
2
. In contrast, 
elongation was greater for uncrosslinked films 
than for crosslinked films. 
 
Drug release data for both uncrosslinked and 
crosslinked films are illustrated in Figures 1 
and 2, respectively. The results showed an 
initial burst release followed by controlled drug 
release for up to 7 days for uncrosslinked 
films (87-95%) and 21 days for crosslinked 
films (70-78 %).   
 
The in vitro antibacterial activity, i.e., 100% 
inhibition of S mutans was found on day 1 with 
formulation C-III, while a similar level of 
antibacterial activity was observed for 
formulations C-III 2 CL and C-III 4CL on days 
3 and 9, respectively. 
 
Scanning electron microscopy (SEM) showed 
differences in the surfaces of the films. The 
upper surface of blank films and ciprofloxacin 
films was smooth, while the surface of films 
containing ciprofloxacin with diclofenac was 
rough. 
 
The degradation rate constant, k, in the 
stability study was calculated at different 
temperatures. The values for different 
formulations ranged from 0.493 to 0.798 
under refrigerated conditions while at room 
and oven temperatures, the values ranged 
from 0.527 to 1.027 and 0.706 to 1.298, 




The optimum drug loading for good, flexible 
films was found to be ≤30%. As the 
concentration of crosslinking agent and/or 
duration of crosslinking increased, the 
physical properties of films such as 
brittleness, tensile strength were altered. The 
drugs incorporated lowered the tensile 
strength and elongation of films, indicating 
that the films had become more brittle.  Thus 
the drugs might have disrupted the linear 
structures of the polymer chains. Tensile 
strength was lower for uncrosslinked films 
than for crosslinked films, due probably to the 
increased toughness and rigidity of the 
polymeric film following crosslinking. 
Conversely, elongation was higher for 
uncrosslinked than for crosslinked films. Film 
thickness was satisfactory. Drug content 
uniformity data suggest good reproducibility of 
the formulation method used. The uncross-
linked films showed greater moisture loss than 
the cross-linked films and this may be due to 
the greater compactness and hence lower 
porosity of the cross-linked films. 
 
In vitro drug release kinetic analysis showed 
that release mechanism for all the films fitted 
best to the Highuchi model, as the plots 
showed high linearity (R
2
 = 0.913 to 0.9533). 
The plot of cumulative drug release per unit 
area versus square root of time in days 









 day for uncrosslinked 
and crosslinked films, respectively.  This is 
confirmed by data based on Korsmeyer et al’s 
equation which showed good linearity (R
2
: 
0.9566 to 0.9958) and with slope (n) values 
ranging from 0.176 to 0.304, indicating that 
zero order diffusion is the prime mechanism of  
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Table 1: Physicochemical characterization (± SE, n = 3) of drug-loaded chitosan films 
 
  PF: Plain Film; C-I: Ciprofloxacin 10%; C-II: Ciprofloxacin 20%; C-III: Ciprofloxacin 30%; CD-I: Ciprofloxacin 20% +         
 Diclofenac sodium 10%; CD-II: Ciprofloxacin 15% + Diclofenac sodium 15%; CD-III: Ciprofloxacin 10%+Diclofenac  
sodium 20%; 2CL: 2-hour cross-linking; 4CL: 4-hour cross-linking 
 
 
drug release. Mass balance studies indicate 
that the drug content did not differ from the 
experimental drug content by more than 3%. 
Findings in respect of in vitro antibacterial 
activity show that crosslinked films exhibited 
antibacterial activity for a longer period (20 
days) than uncrosslinked films (7 days). Thus 
greater crosslinking in crosslinked films 
resulting in more compactness might have 
resulted in a more sustained release of drug 
from the crosslinked films.  
 
Scanning electron microscopy showed that 
the upper surface of plain films was smooth 
while the surface of films containing 
ciprofloxacin and diclofenac sodium was 
rough suggesting that the drug(s) were 
dispersed rather than dissolved in the polymer 
solution prior to film formation. The stability 
results indicate that the films were relatively 
stable (as reflected by reduced k values) 
when stored in a refrigerator and at room 
temperature, compared to those stored in 





The advantages of intra-pocket delivery over 
systemic delivery in periodontitis are that 
administration is less time-consuming than 
mechanical debridement and a lower dose of 
drug would be required to achieve effective 
therapeutic concentration at the site of action.  
The drug-loaded chitosan films were flexible, 
possessed good tensile strength and 
demonstrated satisfactory physicochemical 
characteristics. Although the films showed an 
initial burst release of drug of more than 40%, 
release was sustained for up to 7 and 21 days 
for uncrosslinked and crosslinked films, 
respectively.  Thus chitosan films loaded with 
ciprofloxacin and diclofenac, particularly those 
crosslinked with gluteraldehyde, may have a 




We thank Dr. EVS Subrahmanyam, Principal 
and Dr D Satyanarayana, Research Director, 
PG and Ph.D studies, NGSM Institute of  











PF 1.44 ± 0.01 32.89 ± 0.85 0.99 ± 0.75 0.08 ± 0.02 9.9 ± 0.98 
C-I  1.00 ± 0.01 31.02 ± 1.77 1.08 ± 0.81 0.09 ± 0.01 5.5 ± 1.25 
C-II  1.00 ± 0.01 29.04 ± 1.74 1.23 ± 1.21 0.09 ± 0.01 7.2 ± 1.00 
C-III  0.93 ± 0.03 28.98 ± 1.64 1.42 ± 0.83 0.09 ± 0.02 9.1 ± 1.41 
C-III 2CL 0.82 ± 0.01 28.75 ± 1.45 2.10 ± 0.63 0.10 ± 0.01 9.6 ± 1.41 
C-III 4CL 0.54 ± 0.01 28.78 ± 1.52 2.19 ± 0.75 0.11 ± 0.02 9.3 ± 2.11 
CD-I  0.97 ± 0.01 28.22 ± 1.98 1.64 ± 1.32 0.15 ± 0.01 5.2 ± 1.45 
CD-I 2CL 1.27 ± 0.01 23.22 ± 1.98 1.66 ± 1.63 0.16 ± 0.01 4.9 ± 2.43 
CD-I 4CL 1.92 ± 0.01 16.13 ± 1.98 1.67 ± 1.52 0.16 ± 0.01 4.6 ± 2.21 
CD-II  1.31± 0.01 19.57 ± 1.85 1.89 ± 0.75 0.21 ± 0.02 6.7 ± 0.94 
CD-II 2CL 1.93± 0.01 16.57 ± 1.85 1.90 ± 0.97 0.21 ± 0.02 5.9 ± 1.04 
CD-II 4CL 2.13± 0.01 12.85 ± 1.85 1.91 ± 1.73 0.23 ± 0.02 5.5 ± 1.04 
CD-III  1.87± 0.01 11.71 ± 3.83 2.02 ± 0.35 0.27 ± 0.01 6.9 ± 1.14 
CD-III 2CL 2.48± 0.01 8.71 ± 3.78 2.01 ± 1.52 0.28 ± 0.02 5.9 ± 1.14 
CD-III 4CL 2.71 ± 0.01 6.47 ± 3.81 2.02 ± 1.35 0.29 ± 0.02 5.2 ± 1.14 
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Table 2: Kinetic values obtained from different plots of drug-loaded films   
 















C – I 0.9889 0.9533 0.304         0.9958 
C – II 0.9388 0.8849 0.232 0.9566 
C – III 0.8591 0.9277 0.176 0.9266 
C – III2 CL 0.9658 0.9002 0.265 0.9254 
C – III4 CL 0.9965 0.9165 0.231 0.9374 
CD – I 0.9074 0.9381 0.198 0.9314 
CD – I2 CL 0.9196 0.9063 0.247 0.9782 
CD – I4 CL 0.9063 0.9117 0.275 0.9646 
CD – II 0.9406 0.9130 0.254 0.9669 
CD – II2 CL 0.9301 0.9387 0.234 0.9412 
CD – II4 CL 0.9412 0.9460 0.196 0.9889 
CD – III 0.9198 0.9254 0.240 0.9388 
CD – III2 CL 0.9036 0.9374 0.297 0.9130 
CD – III4 CL 0.9365 0.9145 0.214 0.9387 
 
     C-I: Ciprofloxacin 10%; C-II: Ciprofloxacin 20%; C-III: Ciprofloxacin 30%; CD-I: Ciprofloxacin 20% +    
     Diclofenac sodium 10%; CD-II: Ciprofloxacin 15% + Diclofenac sodium 15%; CD-III: Ciprofloxacin    



































Figure 1: Cumulative drug release from uncrosslinked films  (-♦-) Diclo in CDI,  (-■-)  Cipro in CDI, (-▲-) 
Diclo in CDII  (--) Cipro in CDII, (--) Diclo in CDIII, (-●-) Cipro in CDIII [Diclo:  diclofenac sodium; Cipro: 
ciprofloxacin hydrochloride]  
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Figure 2: Cumulative drug release from 4h - crosslinked films. (-♦-) Diclo in CDI,  (-■-)  Cipro in CDI, (-
▲-) Diclo in CDII  (--) Cipro in CDII, (--) Diclo in CDIII, (-●-) Cipro in CDIII [Diclo:  diclofenac 
sodium; Cipro: ciprofloxacin hydrochloride]  
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